Alexandria Real Estate Equities Faces Class Action Lawsuit with $323.9M Impairment Charge
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: PRnewswire
- Lawsuit Deadline: ClaimsFiler reminds investors that the deadline to file lead plaintiff applications in the securities class action against Alexandria is January 26, 2026, affecting shareholders who purchased securities during the class period from January 27 to October 27, 2025.
- Poor Financial Performance: On October 27, 2025, Alexandria disclosed third-quarter results that fell short of expectations, including a reduction in full-year FFO guidance due to lower occupancy rates and slower leasing activity, resulting in a significant real estate impairment charge of $323.9 million.
- Stock Price Volatility: Following the earnings announcement, Alexandria's stock plummeted from $77.87 on October 27 to $62.94 on October 28, marking a dramatic 19% decline in just one day, reflecting investor concerns over the company's financial stability.
- Legal Liability Risks: The lawsuit alleges that Alexandria and certain executives failed to disclose material information during the class period, violating federal securities laws, which could expose the company to further legal and financial risks, impacting its future market performance.
Analyst Views on ARE
Wall Street analysts forecast ARE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARE is 51.53 USD with a low forecast of 15.84 USD and a high forecast of 67.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
4 Buy
11 Hold
0 Sell
Moderate Buy
Current: 58.090
Low
15.84
Averages
51.53
High
67.00
Current: 58.090
Low
15.84
Averages
51.53
High
67.00
About ARE
Alexandria Real Estate Equities, Inc. is a life science real estate investment trust. The Company is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. It has a Labspace asset base predominantly concentrated in markets with barriers to entry.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
